ELECTROMED INC. DL -,001

At the H.C. Wainwright conference, Electromed presented its business model as a profitable, cash-generating, and debt-free medical device company. Revenue for the last twelve months was about USD 75 million, gross margin roughly 78%, and cash of USD 20 million; the core business is the SmartVest for airway clearance. Management sees an addressable U.S. market potential of about USD 3 billion (around 850,000 potentially untreated patients) and plans to expand direct sales, hospital business, product development, and reimbursement support. Company clinical data indicate substantial reductions in antibiotic use, hospitalizations, and emergency department visits; risks remain concentration on a single product, sales dependence, and reimbursement stability. » More on de.investing.com

Electromed reported diluted earnings per share of $0.39 for Q4, beating the $0.31 estimate, while revenue of $19.41 million narrowly missed projections. Fiscal 2026 marked the 15th consecutive quarter of revenue and earnings growth; annual revenue rose to $73.8 million and gross margin improved to 78.5%. The stock fell about 3.5% after the report as investors reacted to the revenue shortfall, a 29% decline in hospital revenue and the announced CEO resignation in April 2027. Management forecasts double‑digit revenue growth for 2027, continued operating leverage, and plans to expand sales and pursue further operational initiatives. » More on de.investing.com

Jim Cunniff, president and CEO of Electromed, announced that he will retire on April 2, 2027 and will resign his seat on the board of directors. The board has engaged an executive search firm to conduct a nationwide search for his successor. Cunniff has held his current position since 2023; Electromed manufactures, among other products, the SmartVest Airway Clearance System. » More on de.investing.com